Disease relevance of MORICIZINE

• This was a prospective, placebo-controlled, single-blind trial of moricizine (ethmozine) in a dose averaging 10 mg/kg/day in 50 patients, the single entrance criterion being the presence of 10 or more runs of nonsustained ventricular tachycardia (VT) on a screening 24 hr ambulatory electrocardiographic (ECG) recording [1].
• Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design [2].
• Ethmozin, a new antiarrhythmic drug for suppressing ventricular premature complexes [3].
• Complex ventricular arrhythmias associated with the mitral valve prolapse syndrome. Effectiveness of moricizine (Ethmozine) in patients resistant to conventional antiarrhythmics [4].
• The effects of intravenous ethmozine (3 mg.kg-1) on electrophysiological parameters of ischaemically damaged myocardium and induced ventricular tachyarrhythmias were studied by programmed stimulation in 17 conscious dogs with 4 to 8 day-old ligation of the left anterior descending coronary artery [5].

Psychiatry related information on MORICIZINE

• Ethmozin appears to be a well-tolerated, effective antiarrhythmic agent with a dosage regimen that can promote patient compliance for long-term use [6].

High impact information on MORICIZINE

• Differential modulation of autonomic activity by ethmozin and ethacizin (analog of ethmozin) on the canine sinus node and atrioventricular junction [7].
• Ethmozin injections of up to 50 micrograms/ml into the sinus and AV node arteries had no chronotropic or dromotropic effects [7].
• Our findings indicate an antiarrhythmic action of ethmozine in the late stage of myocardial infarction [5].
• Heart rate and blood pressure were not altered by ethmozine either alone or in the combination [8].
• Because of the extensive hepatic metabolism of ethmozine, we investigated the effects of the potent hepatic enzyme inhibitor cimetidine on the kinetics and dynamics of ethmozine [8].

Chemical compound and disease context of MORICIZINE

• We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively [9].
• Comparison of ethmozine to propranolol and the combination for ventricular arrhythmias [10].
• The antiarrhythmic efficacy of moracizin HCl (Ethmozine), a new oral phenothiazine derivative, was evaluated in 20 patients with chronic high-frequency ventricular arrhythmia confirmed by multiple ambulatory electrocardiographic recordings [11].
• A study was made of whether the administration of magnesium or ethmozin to conscious dogs with normal plasma Mg levels (0.75 +/- 0.06 mmol/l) terminates ouabain-induced ventricular tachycardia, an arrhythmia which is dependent on triggered activity resulting from delayed afterdepolarizations [12].

Biological context of MORICIZINE

• At 1 X 10(-2) g.litre-1, ethmozin decreased the rate of rise of phase 0, and slightly reduced action potential amplitude [13].
• Ethmozine did not significantly change the baseline heart rate, blood pressure, and QTc interval from the initial drug-free values [14].
• Alterations in lipid metabolism and cellular morphology in the liver of female rats treated with ethmozine [15].
• Ethmozine had no effect on radionuclide ejection fraction (25.5 +/- 12.7% to 28.2 +/- 13.8%) or cardiac index (2.4 +/- 0.7 to 3.0 +/- 0.6 ml/min/m2) and caused no significant changes in mean aortic, right atrial, pulmonary arterial, or pulmonary capillary wedge pressures [16].
• No change was observed in the oral pharmacokinetics of ethmozine following a single intravenous dose of digoxin, as indicated by the area under the plasma concentration versus time curve, Cmax or Tmax [17].

Anatomical context of MORICIZINE

• Ethmozin had a minor and variable vagolytic action but significantly (p less than 0.05) reduced the sinus node response to sympathetic nerve stimulation [7].
• Ethmozine prolonged the ventricular effective refractory period in normal and infarcted myocardium, and impaired depressed conduction in ischaemically damaged tissue [5].
• Ethmozin (3 to 5 mg/kg-1 i.v.) markedly increased conduction delay in the ischaemic zone of the left ventricle during acute coronary artery occlusion [13].
• Antiarrhythmic effects of ethmozin in cardiac Purkinje fibers: suppression of automaticity and abolition of triggering [18].
• We conclude that ethmozin blocks INa in Purkinje cells in both a non-use-dependent and a use-dependent manner and that the guarded receptor model is useful in describing the use-dependent block [19].

Associations of MORICIZINE with other chemical compounds

• Hence, ethacizin, in contrast to ethmozin, has a direct depressing action on both the sinus node and the AV junction.(ABSTRACT TRUNCATED AT 250 WORDS)[7]
• Block of sodium current (INa) by ethmozin (moricizine), an antiarrhythmic drug, was investigated in isolated, voltage-clamped, canine cardiac Purkinje cells [19].
• Influence of action potential duration and resting potential on effects of quinidine, lidocaine and ethmozin on Vmax in guinea-pig papillary muscles [20].
• The effect of ethacyzine (a diethylamine analogue of ethmozine) on the rapid inward sodium current (INa) was studied in single rat ventricular muscle cells by a patch clamp technique [21].
• Binding of antiarrythmics to phosphatidylcholine membranes appears to be determined mainly by their lipophilicity (r = 0.91), irrespective of the pKa, as demonstrated for ethmozine and lidocaine which showed an excellent fit to the regression line [22].

Gene context of MORICIZINE

• The patients were given for one week ethmozine and then again for one week etacizine, during which periods they were followed echocardiographically, with pressure measurement in the pulmonary artery (PAP) and in the right atrium (RAP) [23].

Analytical, diagnostic and therapeutic context of MORICIZINE

• We also characterized ethmozine block of cardiac sodium channels in isolated neonatal canine ventricular myocytes using the whole cell variation of the patch clamp technique [24].
• The effects of ethmozin were studied on automatic and triggered impulse initiation in isolated canine cardiac Purkinje fibers using standard microelectrode technique [18].
• Further studies comparing VT induction with ambulatory monitoring in patients on ethmozin are needed to confirm these findings and to define the clinical significance of this dissociation [25].
• Serum digoxin concentrations of patients were measured frequently by radioimmunoassay and plasma ethmozine concentrations by high-performance liquid chromatographic methods [26].
• Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation [14].

References